Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 90, Issue 5, 2014, Pages 179-189

  Puri, Basant K ^a   Martins, Julian G ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Academy of Nutritional Medicine   (United Kingdom)

Author keywords

ADHD; DPA; EPA; GLA; Meta analysis; Meta regression

Indexed keywords

DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; EICOSADIENOIC ACID; FATTY ACID ESTER; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; ICOSATRIENOIC ACID; LINOLENIC ACID; POLYUNSATURATED FATTY ACID; STEARIDONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; FATTY ACID ANALYSIS; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INATTENTION; META ANALYSIS; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; STANDARDIZED MEAN DIFFERENCE; STATISTICAL ANALYSIS; SYMPTOM; TREATMENT DURATION; ADOLESCENT; ATTENTION; CHILD; DIET THERAPY; DRUG EFFECTS; FEMALE; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; EICOSAPENTAENOIC ACID; FEMALE; GAMMA-LINOLENIC ACID; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897577027     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.01.004     Document Type: Article

References (85)

1. Wolraich M.L., McKeown R.E., Visser S.N., et al. The prevalence of ADHD: its diagnosis and treatment in four school districts across two States. J. Atten. Disord. 2012, ([PubMed ID: 22956714]).
2. Minkoff N.B. ADHD in managed care: an assessment of the burden of illness and proposed initiatives to improve outcomes. Am. J. Manag. Care 2009, 15:S151-S159. ([PubMed ID: 19601690]).
3. De Ridder A., De Graeve D. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin. Drug Investig. 2006, 26:75-90. ([PubMed ID: 17163238]).
4. Scholtens S., Rydell A.M., Yang-Wallentin F. ADHD symptoms, academic achievement, self-perception of academic competence and future orientation: a longitudinal study. Scand. J. Psychol. 2013, 54:205-212. ([PubMed ID: 23510262]).
5. Drabick D.A., Gadow K.D., Sprafkin J. Co-occurrence of conduct disorder and depression in a clinic-based sample of boys with ADHD. J. Child Psychol. Psychiatry 2006, 47:766-774. ([PubMed ID: 16898990]).
6. Banaschewski T., Brandeis D., Heinrich H., Albrecht B., Brunner E., Rothenberger A. Association of ADHD and conduct disorder - brain electrical evidence for the existence of a distinct subtype. J. Child Psychol. Psychiatry 2003, 44:356-376. ([PubMed ID: 12635966]).
7. Nadder T.S., Rutter M., Silberg J.L., Maes H.H., Eaves L.J. Genetic effects on the variation and covariation of attention deficit-hyperactivity disorder (ADHD) and oppositional-defiant disorder/conduct disorder (Odd/CD) symptomatologies across informant and occasion of measurement. Psychol. Med. 2002, 32:39-53. ([PubMed ID: 11883729]).
8. Knop J., Penick E.C., Nickel E.J., et al. Childhood ADHD and conduct disorder as independent predictors of male alcohol dependence at age 40. J. Stud. Alcohol Drugs 2009, 70:169-177. ([PubMed ID: 19261228]).
9. von Polier G.G., Vloet T.D., Herpertz-Dahlmann B. ADHD and delinquency - a developmental perspective. Behav. Sci. Law 2012, 30:121-139. ([PubMed ID: 22371085]).
10. De Sanctis V.A., Nomura Y., Newcorn J.H., Halperin J.M. Childhood maltreatment and conduct disorder: independent predictors of criminal outcomes in ADHD youth. Child Abuse Negl. 2012, 36:782-789. ([PubMed ID: 23146580]).
11. Lindberg N., Tani P., Porkka-Heiskanen T., Appelberg B., Rimon R., Virkkunen M. ADHD and sleep in homicidal men with antisocial personality disorder. Neuropsychobiology 2004, 50:41-47. ([PubMed ID: 15179019]).
12. Arnold L.E., Abikoff H.B., Cantwell D.P., et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA): design challenges and choices. Arch. Gen. Psychiatry 1997, 54:865-870. ([PubMed ID: 9294378]).
13. The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 1999, 56:1073-1086.
14. Jensen P.S., Arnold L.E., Swanson J.M., et al. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:989-1002. ([PubMed ID: 17667478]).
15. Swanson J.M., Elliott G.R., Greenhill L.L., et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1015-1027. ([PubMed ID: 17667480]).
16. Kilic B.G., Bilgic A., Gurkan K., Aysev A. [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder]. Turk. Psikiyatri Derg. 2007, 18:207-213. ([PubMed ID: 17853975]).
17. Smith B.L. Inappropriate prescribing. Monit. Psychol. 2012, 43:36.
18. L.A. Sroufe, New York Times, Ritalin Gone Wrong. 2012; Available from:. http://www.nytimes.com/2012/01/29/opinion/sunday/childrens-add-drugs-dont-work-long-term.html?pagewanted=1&_r=0.
19. Schmitz F., Scherer E.B., Machado F.R., et al. Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum and hippocampus of juvenile rats. Metab. Brain Dis. 2012, 27:605-612. ([PubMed ID: 22968482]).
20. van der Marel K., Klomp A., Meerhoff G.F., et al. Long-term oral methylphenidate treatment in adolescent and adult rats: differential effects on brain morphology and function. Neuropsychopharmacology 2013, ([PubMed ID: 23851400]).
21. McFadden L., Yamamoto B.K., Matuszewich L. Alterations in adult behavioral responses to cocaine and dopamine transporters following juvenile exposure to methamphetamine. Behav. Brain Res. 2011, 216:726-730. ([PubMed ID: 20817044]).
22. MedlinePlus: Atomoxetine. Available from:. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a603013.html.
23. Stevens L.J., Zentall S.S., Deck J.L., et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 1995, 62:761-768. ([PubMed ID: 7572706]).
24. Burgess J.R., Stevens L., Zhang W., Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 2000, 71:327S-330SS. ([PubMed ID: 10617991]).
25. Colquhoun I., Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med. Hypotheses 1981, 7:673-679. ([PubMed ID: 7196985]).
26. Richardson A.J., Ross M.A. Fatty acid metabolism in neurodevelopmental disorder: a new perspective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot. Essent. Fatty Acids 2000, 63:1-9. ([PubMed ID: 10970706]).
27. Bloch M.H., Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 2012, 50:991-1000. ([PubMed ID: 21961774]).
28. Gillies D., Sinn J., Lad S.S., Leach M.J., Ross M.J. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst. Rev. 2012, 7:CD007986. ([PubMed ID: 22786509]).
29. Sonuga-Barke E.J., Brandeis D., Cortese S., et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am. J. Psychiatry 2013, 170:275-289. ([PubMed ID: 23360949]).
30. Aman M.G., Mitchell E.A., Turbott S.H. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J. Abnorm. Child Psychol. 1987, 15:75-90. ([PubMed ID: 3553274]).
31. Harding K.L., Judah R.D., Gant C. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. Altern. Med. Rev. 2003, 8:319-330. ([PubMed ID: 12946241]).
32. Joshi K., Lad S., Kale M., et al. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot. Essent. Fatty Acids 2006, 74:17-21. ([PubMed ID: 16314082]).
33. Huss M., Volp A., Stauss-Grabo M. Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study. Lipids Health Dis. 2010, 9:105. ([PubMed ID: 20868469]).
34. Sorgi P.J., Hallowell E.M., Hutchins H.L., Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr. J. 2007, 6:16. ([PubMed ID: 17629918]).
35. Yehuda S., Rabinovitz-Shenkar S., Carasso R.L. Effects of essential fatty acids in iron deficient and sleep-disturbed attention deficit hyperactivity disorder (ADHD) children. Eur. J. Clin. Nutr. 2011, 65:1167-1169. ([PubMed ID: 21587279]).
36. Hamazaki T., Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 2004, 58:838. ([PubMed ID: 15116088]).
37. Sinn N. Polyunsaturated fatty acid supplementation for ADHD symptoms: response to commentary. J. Dev. Behav. Pediatr. 2007, 28:262-263. ([PubMed ID: 17565297]).
38. Itomura M., Hamazaki K., Sawazaki S., et al. The effect of fish oil on physical aggression in schoolchildren - a randomized, double-blind, placebo-controlled trial. J. Nutr. Biochem. 2005, 16:163-171. ([PubMed ID: 15741051]).
39. Young G.S., Conquer J.A., Thomas R. Effect of randomized supplementation with high dose olive, flax or fish oil on serum phospholipid fatty acid levels in adults with attention deficit hyperactivity disorder. Reprod. Nutr. Dev. 2005, 45:549-558. ([PubMed ID: 16188207]).
40. Ryan A.S., Nelson E.B. Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: a randomized, placebo-controlled, double-blind study. Clin. Pediatr. (Phila) 2008, 47:355-362. ([PubMed ID: 18180340]).
41. Sinn N., Bryan J., Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot. Essent. Fatty Acids 2008, 78:311-326. ([PubMed ID: 18514501]).
42. Hamazaki K., Syafruddin D., Tunru I.S., et al. The effects of docosahexaenoic acid-rich fish oil on behavior, school attendance rate and malaria infection in school children - a double-blind, randomized, placebo-controlled trial in Lampung, Indonesia. Asia. Pac. J. Clin. Nutr. 2008, 17:258-263. ([PubMed ID: 18586645]).
43. Johnson M., Mansson J.E., Ostlund S., et al. Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. Atten. Deficit Hyperact. Disord. 2012, 4:199-204. ([PubMed ID: 22753087]).
44. Brue A.W., Oakland T.D., Evans R.A. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci. Rev. Altern. Med. 2001, 5:187-194. ([PubMed ID]).
45. Hirayama S., Hamazaki T., Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 2004, 58:467-473. ([PubMed ID: 14985685]).
46. Raz R., Carasso R.L., Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J. Child Adolesc. Psychopharmacol. 2009, 19:167-177. ([PubMed ID: 19364294]).
47. Bélanger S.A., Vanasse M., Spahis S., et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr. Child Health 2009, 14:89-98. ([PubMed ID: 19436468]).
48. Perera H., Jeewandara K.C., Seneviratne S., Guruge C. Combined omega3 and omega6 Supplementation in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment: a Double-Blind, Placebo-Controlled Study. J. Child Neurol. 2012, 27:747-753. ([PubMed ID: 22596014]).
49. Perera H., Jeewandara K.C., Seneviratne S., Guruge C. Assessment of outcome of an ADHD treatment program using parent feedback. Sri Lanka J. Psychiatry 2010, 1:51-55.
50. Bussing R., Fernandez M., Harwood M., et al. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 2008, 15:317-328. ([PubMed ID: 18310593]).
51. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 1996, 17:1-12. ([PubMed ID: 8721797]).
52. Bax L., Yu L.M., Ikeda N., Moons K.G. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med. Res. Methodol. 2007, 7:40. ([PubMed ID: 17845719]).
53. Martins J.G., Bentsen H., Puri B.K. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol. Psychiatry 2012, 17:1144-1149. ([PubMed ID: 22488258]).
54. Arnold L.E., Kleykamp D., Votolato N.A., Taylor W.A., Kontras S.B., Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol. Psychiatry 1989, 25:222-228. ([PubMed ID: 2539203]).
55. Sinn N., Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J. Dev. Behav. Pediatr. 2007, 28:82-91. ([PubMed ID: 17435458]).
56. Voigt R.G., Llorente A.M., Jensen C.L., Fraley J.K., Berretta M.C., Heird W.C.A. randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 2001, 139:189-196. ([PubMed ID: 11487742]).
57. Puri B.K. Cardiovascular disease and depression: the PUFA connection. Int. J. Clin. Pract. 2008, 62:355-357. ([PubMed ID: 18261068]).
58. Kavanagh T., Lonergan P.E., Lynch M.A. Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:391-397. ([PubMed ID: 15041032]).
59. Puri B.K. Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J. Clin. Pathol. 2007, 60:122-124. ([PubMed ID: 16935966]).
60. Chen J.R., Hsu S.F., Hsu C.D., Hwang L.H., Yang S.C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J. Nutr. Biochem. 2004, 15:467-472. ([PubMed ID: 15302081]).
61. Mitchell E.A., Aman M.G., Turbott S.H., Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin. Pediatr. (Phila) 1987, 26:406-411. ([PubMed ID: 2439249]).
62. Martins J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr. 2009, 28:525-542. ([PubMed ID: 20439549]).
63. Richardson A.J., Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115:1360-1366. ([PubMed ID: 15867048]).
64. Puri B.K., Richardson A.D. The effects of olive oil on omega3 fatty acids and mood disorders. Arch. Gen. Psychiatry 2000, 57:715. ([PubMed ID: 10891044]).
65. Richardson A.J., Puri B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:233-239. ([PubMed ID: 11817499]).
66. Stevens L., Zhang W., Peck L., et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38:1007-1021. ([PubMed ID: 14669965]).
67. Johnson M., Ostlund S., Fransson G., Kadesjo B., Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J. Atten. Disord. 2009, 12:394-401. ([PubMed ID: 18448859]).
68. Vaisman N., Kaysar N., Zaruk-Adasha Y., et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am. J. Clin. Nutr. 2008, 87:1170-1180. ([PubMed ID: 18469236]).
69. Kairaluoma L., Narhi V., Ahonen T., Westerholm J., Aro M. Do fatty acids help in overcoming reading difficulties? A double-blind, placebo-controlled study of the effects of eicosapentaenoic acid and carnosine supplementation on children with dyslexia. Child Care Health Dev. 2009, 35:112-119. ([PubMed ID: 18991979]).
70. Gustafsson P.A., Birberg-Thornberg U., Duchen K., et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010, 99:1540-1549. ([PubMed ID: 20491709]).
71. Manor I., Magen A., Keidar D., et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur. Psychiatry 2011, ([PubMed ID: 21807480]).
72. Milte C.M., Parletta N., Buckley J.D., Coates A.M., Young R.M., Howe P.R. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 2012, 28:670-677. ([PubMed ID: 22541055]).
73. Richardson A.J., Burton J.R., Sewell R.P., Spreckelsen T.F., Montgomery P. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One 2012, 7:e43909. ([PubMed ID: 22970149]).
74. Conners C.K. A teacher rating scale for use in drug studies with children. Am. J. Psychiatry 1969, 126:884-888. ([PubMed ID: 4900822]).
75. Goyette C.H., Conners C.K., Ulrich R.F. Normative data on revised Conners Parent and Teacher Rating Scales. J. Abnorm. Child Psychol. 1978, 6:221-236. ([PubMed ID: 670589]).
76. Conners C.K. Conners[U+05F3] Parent Rating Scales - Revised 1997, Multi-Health Systems, New York.
77. Conners C.K. Conners[U+05F3] Abbreviated Symptom Questionnaire 1990, Multi-Health Systems, New York.
78. Conners C.K. Conners Rating Scales - Revised: Technical Manual 2000, Multi-Health Systems, New York.
79. Conners C.K. Conners[U+05F3] Rating Scales Manual 1990, Multi-Health Systems, Toronto.
80. Conners C.K. Conners[U+05F3] Rating Scales Manual 1989, Multi-Health Systems, North Tonawanda (NY).
81. Ullmann R.K., Sleator E.K., Sprague R.L. A new rating scale for diagnosis and monitoring of ADD children. Psychopharmacol. Bull. 1984, 20:160-164. ([PubMed ID: 6718641]).
82. Zhang S., Faries D.E., Vowles M., Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int. J. Methods Psychiatr. Res. 2005, 14:186-201. ([PubMed ID: 16395872]).
83. Achenbach T.M., Edelbrock K.C. Manual for the Child Behavior Checklist and Revised Child Behavior Profile 1983, University of Vermont Department of Psychiatry, Burlington (VT).
84. Pelham W.E., Gnagy E.M., Greenslade K.E., Milich R. Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. J. Am. Acad. Child Adolesc. Psychiatry 1992, 31:210-218. ([PubMed ID: 1564021]).
85. Quay H.C. A dimensional approach to children[U+05F3]s behavior disorders: the revised behavior problem checklist. Sch. Psychol. Rev. 1983, 12:244-249.